title: Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment.
authors.forename: F
authors.initials: F
authors.lastname: Cisarò
authors.forename: M
authors.initials: M
authors.lastname: Astegiano
authors.forename: C
authors.initials: C
authors.lastname: De Angelis
authors.forename: G
authors.initials: G
authors.lastname: Saracco
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
authors.forename: R
authors.initials: R
authors.lastname: Pellicano
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D054328:Proton Pump Inhibitors; D008795:Metronidazole; C073340:ranitidine bismuth citrate; D000658:Amoxicillin; D011899:Ranitidine; D017291:Clarithromycin; D001729:Bismuth